TrialDiabetologia2018

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Naveed Sattar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.